A new standard of care has been established by the Food and Drug Administration (FDA) by approving the use of low-molecular-weight heparin (LMWH) for the treatment of deep vein thrombosis (DVT) in the home setting. Patients diagnosed with a DVT and who meet specific criteria can be treated with LMWH injections at home. LMWH doses are administered based on the patient’s weight, once or twice daily. Warfarin (Coumadin) is administered concomitantly beginning on day one or two of LMWH therapy. Heparin therapy is continued for a minimum of five days and is discontinued only after the patient’s International Normalized Ratio (INR) has been therapeutic (2.0-3.0) for two consecutive days. The anticoagulation service staff is accustomed to managing, educating and arranging follow-up care for DVT patients being treated at home.